NEW YORK, April 29, 2018 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ulta Beauty, Inc. (NASDAQ:ULTA) from March 30, 2016 through February 23, 2018, inclusive (the “Class Period”) of the important May 1, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Ulta Beauty investors under the federal securities laws.
To join the Ulta Beauty class action, go to https://www.rosenlegal.com/cases-1304.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Ulta Beauty was engaged in the widespread practice of repackaging returned cosmetics and re-shelving them alongside unblemished products to sell at full retail price; and (2) as a result, Ulta Beauty’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 1, 2018.
A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to https://www.rosenlegal.com/cases-1304.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Zachary Halper, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. The Rosen Law Firm was Ranked No. 1 by Institutional Shareholder Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Zachary Halper, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 



